Physician profile
Scott Baxter
NPI 1457897258
$8,295.02
in general payments reported to CMS, 2019-2025
17 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,423 · 2022: $2,314 · 2023: $2,055 · 2024: $1,339 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,557.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,359.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,131.05 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $1,081.71 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $551.36 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $436.20 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $430.85 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.94 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $199.19 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $198.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $181.76 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $175.37 | 2021-2022 | |
| Lundbeck LLC | $66.08 | 2022-2023 | Rexulti |
| Corium, LLC | $41.02 | 2024 | Azstarys |
| Gilead Sciences, INC. | $22.95 | 2024 | |
| Vanda Pharmaceuticals INC. | $22.63 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $18.77 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.62 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.